Merck and Ridgeback Biotherapeutics reported that molnupiravir reduced the risks of hospitalization or death from 9.7% to 6.8%, according to a press release by Merck on Friday.
- In the updated results, nine deaths were reported in the placebo group and one in the molnupiravir group.
- The planned interim analysis revealed that molnupiravir largely reduced the risks of hospitalization or death from 14.1% in the place group to 7.3% in the molnupiravir group.
- The analyses support the efficacy and positive benefit-risks assessment of molnupiravir for treating mild to moderate COVID-19 in adults at high risk for worsening progression.
- Molnupiravir received approval for use in the U.K. The investigational drug is under review by FDA for Emergency Use Authorization.
Merck and Ridgeback Biotherapeutics have performed a rigorous development initiative for molnupiravir and believe it addressed unmet medical needs for adults with COVID-19. MRK down 4.40%.